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Abstract
Purpose There is an annual incidence of 50,000 glioma cases in Europe. The optimal treatment strategy is highly per-
sonalised, depending on tumour type, grade, spatial localization, and the degree of tissue infiltration. In research settings, 
advanced magnetic resonance imaging (MRI) has shown great promise as a tool to inform personalised treatment decisions. 
However, the use of advanced MRI in clinical practice remains scarce due to the downstream effects of siloed glioma imaging 
research with limited representation of MRI specialists in established consortia; and the associated lack of available tools 
and expertise in clinical settings. These shortcomings delay the translation of scientific breakthroughs into novel treatment 
strategy. As a response we have developed the network “Glioma MR Imaging 2.0” (GliMR) which we present in this article.
Methods GliMR aims to build a pan-European and multidisciplinary network of experts and accelerate the use of advanced 
MRI in glioma beyond the current “state-of-the-art” in glioma imaging. The Action Glioma MR Imaging 2.0 (GliMR) was 
granted funding by the European Cooperation in Science and Technology (COST) in June 2019.
Results GliMR’s first grant period ran from September 2019 to April 2020, during which several meetings were held and 
projects were initiated, such as reviewing the current knowledge on advanced MRI; developing a General Data Protection 
Regulation (GDPR) compliant consent form; and setting up the website.
Conclusion The Action overcomes the pre-existing limitations of glioma research and is funded until September 2023. New 
members will be accepted during its entire duration.
Keywords Glioma · Advanced MRI · Multi-disciplinary · Networking · Translational research · COST action
1  State‑of‑the‑Art MR Imaging for Glioma
In Europe, approximately 50,000 new cases of glioma 
(brain tumours originating from glial cells) occur each year 
[1], with numbers constantly rising with an aging Euro-
pean population. Median survival ranges from more than 
10 years for low-grade glioma, to only 14.6 months for the 
most aggressive forms of glioma, namely glioblastoma [2]. 
Survival increases when the tumour is diagnosed accurately 
early on and an appropriate course of treatment is applied. 
However, screening and management are limited due to the 
heterogeneity in tumour growth dynamics, as well as the 
high inter- and intra-tumoral biological spatial heterogeneity 
[3]. Currently, there is increasing interest in advanced imag-
ing techniques to identify the most malignant regions within 
the tumour according to the 2016 World Health Organisation 
(WHO) Brain Tumour Classification [4]. This understanding 
will help shape the highly-personalised therapy necessary 
for glioma and allow for the development of biomarkers for 
early tumour diagnosis and treatment planning [3].
Magnetic resonance imaging (MRI) is the diagnostic 
modality of choice to investigate the structure and physiol-
ogy of brain tissue. It is a widely available and non-inva-
sive medical imaging tool and the only modality to deliver 
information of brain tissue at a sufficient contrast, spatial 
and temporal resolution [5, 6]. While conventional MRI 
techniques assess anatomical information about the struc-
ture of brain tissue and vasculature, advanced MRI tech-
niques can measure dynamic and functional processes such 
as perfusion [using arterial spin labeling (ASL), dynamic 
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contrast enhanced (DCE), and dynamic susceptibility con-
trast (DSC)] [7, 8], metabolism [using MR spectroscopy 
(MRS)] [9], microstructure [using diffusion kurtosis imag-
ing (DKI), intravoxel incoherent motion (IVIM) [10], and 
other diffusion MRI techniques] [11–13], stiffness [using 
magnetic resonance elastography (MRE)] [14], oxygen 
extraction [using BOLD-MRI] [15], and vessel architecture 
[using vessel architectural imaging (VAI)] [16]. Examples 
of these conventional and advanced MRI techniques are pro-
vided in Fig. 1. The resulting quantitative information can 
be used to categorize and discriminate gliomas better than 
using anatomical image sequences alone [6].
The development of advanced techniques to become 
MRI biomarkers has progressed through the combination 
of MRI approaches (multi-modality) and through data-
driven approaches to combine images with genetic and 
clinical information—where “radiomics” often plays a vital 
role [9, 17, 18]. Growing evidence highlights the impor-
tance of combining biomarkers to non-invasively map the 
heterogeneous microenvironment of brain tumours [19–21]. 
This is critical for a more reliable glioma assessment and, 
therefore, an optimally individualized treatment approach 
[19, 20]. Additionally, the extraction of a large number of 
informative features from imaging, genetics, and clinical 
assessments that are subjected to machine learning-based 
analyses (radiomics), can be used to aid diagnosis and to 
predict treatment response for an individual patient [20, 22]. 
This approach is highlighted by the WHO classification of 
gliomas updated in 2016 [4] which stated that the key prog-
nostic determinants in glioma are genomic and proteomic, 
rather than histopathological, analyses including mutations 
in isocitrate dehydrogenase (IDH), alpha-thalassemia/mental 
retardation syndrome X-linked (ATRX), tumour protein p53 
and  O6‐alkylguanine DNA‐alkyltransferase MGMT genes 
and 1p/19q co-deletion which have already been shown to 
influence glioma malignancy and treatment response [4, 23].
In clinical practice, some advanced MRI techniques are 
already frequently used to support the monitoring of patients 
diagnosed with glioma before, during, and after treatment 
[8]. MRI offers the ability to perform non-invasive, repeated 
examinations with minimum risk for the patient [6, 8]. First, 
advanced MRI is optimal for target delineation during radio-
therapy (RT) treatment planning, as novel MRI biomarkers 
lead to the improved localisation and determination of the 
extent of the tumour [24]. For example, diffusion kurtosis 
imaging (DKI) may detect early anomalies in tissue micro-
structure by tumour infiltration, not depicted on morphologi-
cal MRI [11, 13]. Moreover, MRI can also be used for RT 
treatment planning instead of computed tomography (CT) 
which reduces radiation exposure and avoids MRI to CT 
co-registration errors. While the attenuation property of tis-
sue is directly linked to the voxel intensity in CT, with MRI 
it is indirectly linked and typically has to be estimated by 
a combination of atlas-based and intensity-based machine 
learning methods, usually using T1-weighted or Ultra-short 
Echo-Time (UTE) sequences [25]. Secondly, treatment 
monitoring is important for patients diagnosed with low-
grade glioma, for whom early and aggressive treatments 
do not necessarily lead to improved overall survival [26]. 
Novel physiological parameters resulting from advanced 
MRI techniques, such as 1H-MRS and DSC, can serve as 
early markers for progression from low to high-grade glioma 
[27]. In high grade glioma, the accurate determination of 
treatment response to distinguish tumour progression from 
radiation necrosis and pseudoprogression is vital for man-
agement decisions [8, 28]. In contrast to conventional MRI, 
advanced MRI techniques, such as chemical exchange satu-
ration transfer (CEST), MRS and MR perfusion, have shown 
the potential to distinguish treatment effects, such as radia-
tion necrosis and pseudoprogression, from true tumour pro-
gression. Thus, the application of those techniques greatly 
improves timely and accurate decisions on further patient 
management [29–31]. Lastly, glioma treatment is associated 
with brain damage, both within and remote from the primary 
target region of treatment [29, 32]. Studies are emerging that 
investigate the side-effects of different treatment strategies 
(e.g. radiation, chemotherapy, or both) on the brain structure 
and function, which lead to a reduced quality of life.
For research purposes, a plethora of different advanced 
MRI methods has been explored to help investigate, develop, 
and improve novel treatment strategies for glioma. More spe-
cifically, advanced MRI techniques are being used to study 
in vivo glioma pathophysiology, for example, using CEST 
[33]. Additionally, the techniques have the potential to iden-
tify novel targets for treatment [28] and are used to investi-
gate mechanisms of treatment effects both on pathological 
and healthy tissue using MR techniques such as ASL, DCE, 
and diffusion MRI [32, 34, 35]. As an example, non-inva-
sive physiological biomarkers are being developed for the 
early identification of adverse treatment effects on healthy 
tissues [34]. Whilst current practice mitigates the effects of 
RT by avoiding where possible exposure of the brainstem, 
hippocampus, and cranial nerves [36], little is known about 
individual tolerance to chemo-radiation and its association 
with long-term changes in cognition and quality of life [32, 
37]. Biomarkers, based on advanced MRI, have the potential 
to better identify structures at risk and detect adverse effects 
at an early stage. This approach could allow personalised 
therapy and facilitate a timely therapy adaptation to mini-
mize adverse effects. Furthermore, advanced MRI has great 
potential for use in clinical trials by optimising patient selec-
tion by exploiting the excellent sensitivity of MRI to the 
heterogeneous microenvironment of glioma, as well as the 
capability for treatment response monitoring and differen-
tiating treatment response from tumour progression [8, 28].
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In summary, advanced MRI techniques might aid in 
the detection, diagnosis, treatment planning, assessment 
of treatment response, and prognosis of gliomas and fulfill 
a key role in the personalised management of glioma in 
clinical practice, as well as in many research initiatives 
focussing on the mechanisms of pathophysiology and 
novel treatment strategies.
Fig. 1  Examples of conventional and advanced MRI methods. Bio-
markers highlighting tumour structure from left to right: T1-weighted 
after injection of a gadolinium based contrast agent, T2-weighted, 
fluid-attenuated inversion recovery (FLAIR), susceptibility weighted 
imaging (SWI), apparent diffusion coefficient (ADC); biomark-
ers highlighting tumour physiology: arterial spin labeling (ASL), 
dynamic susceptibility contrast (DSC), dynamic contrast enhanced 
(DCE), magnetic resonance elastography (MRE), vessel architec-
tural imaging (VAI), intravoxel incoherent motion (IVIM) perfusion, 
functional MRI (fMRI); biomarkers highlighting tumour metabolism: 
amide proton transfer chemical exchange saturation technique (APT 
CEST), magnetic resonance spectroscopy; biomarkers highlighting 
healthy tissue biomarkers: grey matter (GM) volume, ASL, and frac-
tional anisotropy (FA) [34, 70]
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2  Lack of Harmonization Hampers 
Widespread Use in Research and Clinic
Despite its clear potential, and with the exception of diffu-
sion-weighted imaging (DWI) [38] and dynamic suscep-
tibility contrast (DSC) [38, 39], advanced MRI methods 
are scarcely used in clinical practice of glioma diagnostics. 
The application of advanced MRI is hampered by a scat-
tered research landscape for glioma-related MRI develop-
ment, lack of tools readily available for clinical applica-
tions, and limited presence in established consortia for 
research and clinical application in glioma.
Regardless of the relatively high incidence of glioma in 
Europe [1], advanced MRI studies are often designed to 
answer specific questions, related to a single experimen-
tal sequence only. As a consequence, the acquired data 
may not be directly transferable to other institutions for 
use in larger multi-centre, multi-source studies aimed at 
validating these methods [40]. This is further aggravated 
by several factors causing even more fragmentation of 
research group efforts. Despite the efforts of some highly 
successful European research organisations, such as the 
European Organisation for Research and Treatment of 
Cancer (EORTC) [41], the research harmonisation at the 
pan-European level, equivalent to the National Institutes of 
Health (NIH) in the United States, is lacking. The lack of 
coordination between the efforts of research groups results 
in a scattered research landscape with a wide variety of 
local expertise and research focus [8, 38]. The current eco-
nomic gradients contributing to the general “brain drain” 
towards northern and western Europe, concentrating the 
expertise in the bigger academic centres exacerbates this 
variety [42]. Local differences in languages and legisla-
tions further complicate inter-institutional exchange [43]. 
Although not immediately evident, this scattered research 
landscape might constrain patient participation in leading-
edge research which limits recruitment numbers, causes 
selection bias and deprives patients from being able to 
contribute to scientific advancement.
Because advanced MRI methods are often resource-
heavy and require unique expertise, MRI acquisition pro-
tocols may differ between sites or be excluded altogether 
in a research setting [8, 38]. Further inconsistencies in 
imaging are caused by the broad range of approaches for 
subsequent image analysis and interpretation [8, 38]. This 
is especially problematic if optimal in vivo characterisa-
tion of glioma should include multiple conventional and 
advanced MRI parameters [44].
The Brain Imaging Data Structure (BIDS) [45], 
Quantitative Imaging Network (QIN) [46], Quantitative 
Imaging Biomarkers Alliance (QIBA) [47],  European 
Imaging Biomarker Alliance (EIBALL) [48] and Open 
Source Initiative for Perfusion Imaging (OSIPI) [49] 
initiatives have recently made efforts to develop stand-
ards for data acquisition, sharing, and processing. These 
endeavours comprise not only formulating recommenda-
tions for conventional MRI [50], but also for advanced 
MRI techniques in certain targeted patient populations. 
More specifically, this includes consensus recommenda-
tions for DSC in high-grade gliomas [51], brain perfusion 
imaging acquisition and processing recommendations for 
ASL [52, 53], or functional (f)MRI recommendations for 
pre-treatment planning and follow-up [54]. Despite such 
efforts, approaches for the harmonisation of data acqui-
sition, recommendations for the optimal combination of 
MRI-biomarkers, and standardised open-source data anal-
ysis software for post-processing are currently not widely 
accepted, implemented or available.
Additionally, there are well-established consortia with a 
focus on glioma research, specifically focussing on new and 
improved treatment strategies. However, despite the pres-
ence of such collaborative networks throughout Europe or 
with European participation, such as EORTC [41], Response 
Assessment in Neuro-Oncology (RANO) [55], European 
Association of Neuro-Oncology (EANO) [56], Consor-
tium to Inform Molecular and Practical Approaches to CNS 
Tumor Taxonomy (cIMPACT) [57], or Glioma Longitudinal 
Analysis Consortium (GLASS) [58] brain tumour groups, 
the European advanced MR imaging research community 
only has limited representation in these consortia. In con-
clusion, there is limited use of advanced MRI for glioma 
diagnostics because there is not an optimal critical mass of 
multidisciplinary experts in the field of glioma research and 
advanced MRI.
In summary, the current research conditions hamper 
advanced MRI to reach its full potential for glioma diag-
nostics. Ultimately, these shortcomings complicate the 
formation of big data sets, delay scientific breakthroughs 
for novel treatment strategy developments, complicate the 
development of radiomics approaches for glioma, and result 
in stagnating progress towards personalised medicine for this 
patient group. Large, longitudinal studies are key to finding 
associations between glioma treatment and MRI biomark-
ers as well as patient outcomes including long-term quality 
of life and cognitive capacity. These findings might lead to 
successful tools for patient monitoring and early prediction 
of patient outcomes.
3  CA18206: Glioma MR Imaging 2.0
To overcome these complex obstacles that hinder the 
progress of advanced MRI research in glioma, a group 
of European researchers strove to connect the imaging 
and non-imaging communities and to develop a powerful 
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pan-European, multidisciplinary consortium of researchers 
and clinicians, patient organisations, data scientists, and MR 
imaging scientists. The proposed Action towards this goal, 
named ‘Glioma MR Imaging 2.0 (GliMR)’, was funded for 
four years (Sep 2019—Sep 2023) by the European Coop-
eration in Science and Technology (COST) in June 2019, 
at present connecting over 150 clinicians, engineers, and 
physicists from 26 European countries,1 one COST Near 
Neighbour Country (Morocco) and three International 
Partner Countries (Canada, the United States and Brasil), 
(Fig. 2) [59, 60].
GliMR focuses on creating a network in which the gli-
oma imaging community within Europe is connected, coor-
dinates the development of advanced MRI biomarkers and 
the collection of datasets across Europe, as well as stimulat-
ing their use in research and clinical settings. Through the 
organisation of international meetings and funding calls for 
research exchanges and conference attendance, the Action 
aims to reach a state of maximal progress in the develop-
ment and application of advanced MR imaging for improved 
decision making in the diagnosis, patient monitoring, and 
assessment of treatment response in clinical trials and clini-
cal practice. The Action aims to go beyond the state-of-the-
art in glioma imaging by accelerating the use of advanced 
MRI for glioma in four focus areas: tumour characterisation, 
identification of regions at risk for progression, assessment 
of disease progression, and evaluation of treatment-related 
adverse effects. GliMR will apply new insights to stimulate 
innovation in personalised clinical management strategies, 
aiming at the refinement of diagnosis and the assessment 
of disease progression, the minimisation of adverse effects 
of treatment, and eventually the improvement of the long-
term health-related quality of life of the patient. GliMR is 
structured in five Working Groups (Fig. 3), each with its 
own specific focus, aims and milestones, as summarized 
on the timeline in Fig. 4. All are collaborating to achieve 
the main goal of the Action: (1) Advanced MRI biomarkers 
for glioma characterisation, (2) Multi-site data integration, 
(3) Clinical translation, (4) Stakeholder relations, and (5) 
Dissemination. 
The Working Group ‘Advanced MRI biomarkers for 
glioma characterisation’ focusses on the identification and 
quantification of advanced MRI biomarkers for application 
in glioma by sharing knowledge, as well as promoting best 
practices. Current knowledge on the most pertinent, exist-
ing, advanced MRI biomarkers and the methods to combine 
those with data from psychological assessments, genetics, 
and histology, as well as the technology readiness level of 
current data analysis methods, will be assessed by review-
ing the state-of-the-art literature. As an example, the ASL-
analysis toolbox ExploreASL has recently been launched, 
allowing the pooling of multi-centre ASL datasets, increas-
ing comparability and narrowing the gap between clinicians, 
researchers and developers [53]. Special attention will be 
given to identify existing gaps in the current analysis and 
use of glioma biomarkers, which is in line with the goals of 
QIN [46] and OSIPI [49]. Additionally, combined pipelines 
for advanced MRI in glioma will be distributed on open-
access platforms to promote best practices for analysis. Con-
sequently, this working group will lift the current necessity 
of having in-house expertise and software for the applica-
tion of advanced MRI biomarkers for glioma diagnostics in 
both research and clinical settings and work towards analysis 
standardization.
Working Group ‘Multi-site data integration’ coordinates 
the development of tools and guidelines for multi-site data 
integration which will enable the creation of large datasets in 
Fig. 2  Geographical visualisation of GliMR’s participants within 
and outside Europe. Number of participants per European country is 
given, as well as the Near Neighbour Countries and the International 
Partner Countries [60]
1 Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Cro-
atia, Cyprus, Czech Republic, Denmark, Estonia, France, Germany, 
Greece, Ireland, Italy, North Macedonia, Malta, Morocco, Norway, 
Poland, Portugal, Romania, Serbia, Slovakia, Spain, Switzerland, The 
Netherlands, Turkey, UK, USA.
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glioma diagnostics. This working group will tackle issues on 
data privacy, data infrastructure and data portability. In the 
field of data privacy, this working group focuses on stand-
ardizing informed consent for patients and participants in 
glioma imaging research.. Existing standards on data privacy 
and resources for data exchange will be reviewed, resulting 
in guidelines and multilingual consent compliant to the Gen-
eral Data Protection Regulation (GDPR). In addition, exist-
ing tools and databases for data sharing will be reviewed 
and guidelines on the use of those data infrastructures will 
be drafted. Also, data portability issues will be investigated, 
as pooling existing datasets from multiple imaging sites is 
complex. For example, the European Network for Brain 
Imaging of Tumours (ENBIT) offers a repository for brain 
imaging data, as well as tools for data processing [61, 62]. 
Such existing datasets are highly heterogeneous, caused by 
factors such as varying imaging instruments, machine-spe-
cific artefacts and differences in MRI-sequences as well as 
from subtle variations in how the procedures are performed 
within the clinical setting. Therefore, a common data struc-
ture for storage and conveyance of advanced MRI (meta)
data will be specified, and the international BIDS standard 
will be extended for advanced MRI sequences [45]. Other 
projects facilitating data sharing, such as the development of 
sequence-specific lexicons, following the example of OSIPI 
for ASL and DSC/DCE [49], will be supported. These tools 
will facilitate a multi-site data integration approach to go 
beyond the use of small local datasets on glioma imaging.
The Working Group ‘Clinical translation’ fosters cross-
border information exchange of past, current, and future 
clinical glioma trials and studies. This group will create a 
European-wide overview of past and ongoing glioma stud-
ies that apply advanced MRI. Next, it will stimulate and 
coordinate the submission of multi-site grant applications 
to national, European, and international funding bodies 
for retrospective and prospective studies, using tools and 
knowledge provided by the first two Working Groups. This 
approach will accelerate ground-breaking progress in the 
development of MRI biomarkers for glioma, as well as 
the application of radiomics. Additionally, advanced and 
patient-friendly MRI-protocols and guidelines will be devel-
oped, to gather prospective glioma imaging data. Although 
guidelines were already formulated for conventional MRI in 
brain tumour imaging [50] as well as for specific advanced 
MRI techniques in different neurological indications [52], 
similar recommendations for advanced MRI in glioma are 
lacking. These protocols and guidelines should both be 
feasible within an academic and a clinical setting. For this 
Fig. 3  PERT chart of the structure within GliMR. Note the interaction between the Working Groups via various routes, denoted by coloured 
arrows. Communication between the Action and the general public will be ensured through Working Group 5
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purpose, the Working Group will also seek input from hos-
pital staff members for daily clinical practice, such as nurses 
and radiographers, as well as from patient organisations, 
representing the interest of patients diagnosed with glioma.
The fourth Working Group ‘Stakeholder relations’ 
ensures representation of all relevant stakeholders within 
GliMR, initiates collaborations with stakeholders inside 
and outside the network, and coordinates the communica-
tion between all stakeholders. Liaisons with stakeholders 
within the fields of glioma and/or MR imaging will be set-
up, including key international consortia and organisations 
with a focus on glioma and/or imaging biomarkers research, 
industrial collaborators, clinical practice, local and national 
European policy makers, patient organisations, as well 
as relevant ongoing COST Actions groups. Also, other 
organisations and institutes with complementary expertise 
and data, such as those related to neuropsychology, neuro-
oncology, neurosurgery, molecular biology, pathology, and 
genetics will be identified and collaborations will be initiated 
to provide input to the first three Working Groups.
Working Group ‘Dissemination’ supports the other Work-
ing Groups in the dissemination of their goals and results, in 
manners tailored to the research community in- and outside 
this Action, clinical practice, patient organisations and the 
general public. This working group maintains several com-
munication channels such as the GliMR website (www.glimr 
.eu), social media accounts [63] and newsletters, and trans-
lates important news into layman’s terms for dissemination 
via patient organisations and popular media. It will support 
the other Working Groups in drafting guidelines and best 
practice documentation to inform participants.
In order to reach the goals of the network and the working 
groups, GliMR provides opportunities to network, collabo-
rate, discuss, investigate, teach and learn. The Action facili-
tates and organises (teleconference) meetings and scientific 
and clinical training schools. Additionally, GliMR has open 
funding calls for laboratory exchanges (short-term scientific 
missions) and conference grants for participants affiliated to 
institutions in inclusiveness target countries, as defined by 
the COST Association2 [64].
4  GliMR’s Output After Grant Period One
GliMR’s first grant period ended in April 2020. Throughout 
this period of seven months, several meetings were held, 
giving the participants the opportunity to network, collabo-
rate, and discuss glioma research. A kick-off management 
meeting was organised in September 2019. In October 2019, 
GliMR hosted a meet-and-greet session during the 36th 
Annual Scientific Meeting of the European Society for Mag-
netic Resonance in Medicine and Biology (ESMRMB) (Rot-
terdam, the Netherlands). Also, a two-day scientific meeting 
was held in Malta in December 2019, bringing together over 
60 participants. Additionally, a call for Short-Term Scientific 
Missions (STMS) was launched, which offers (early-career) 
researchers the opportunity to travel to another participating 
research centre for a certain period, during which a collabo-
ration is set up and a research project is carried out. In total, 
four STSMs finished successfully despite the COVID-19 
pandemic, focussing on the improvement of a DSC analysis 
pipeline, the prediction of survival using DSC and ASL in 
glioblastoma, and on the application of machine learning 
and deep learning on the analysis of perfusion and diffusion 
MRI as a biomarker for glioma.
Several projects were also initiated by the different 
Working Groups. The Working Groups ‘Advanced MRI 
biomarkers for glioma characterisation’ and ‘Clinical trans-
lation’ have initiated the development of three literature 
reviews. These reviews will provide an overview of the 
currently available advanced MRI techniques for glioma 
Fig. 4  GliMR’s milestones throughout the 4-year lifespan of the 
Action, from June 2019 until April 2023. Each icon represents one of 
the Working Groups: ‘brain’: Advanced MRI biomarkers for glioma 
characterisation; ‘laptop’: ‘Multi-site data integration’; ‘star’: ‘Clini-
cal translation’. The goals of the remaining two Working Groups are 
ongoing, therefore, not included in this timeline
2 Albania, Bosnia and Herzegovina, Bulgaria, Cyprus, Czech Repub-
lic, Estonia, Croatia, Hungary, Lithuania, Latvia, Luxembourg, Malta, 
Moldova, Montenegro, Poland, Portugal, Romania, Slovenia, Slova-
kia, Republic of North Macedonia, Republic of Serbia and Turkey.
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characterisation, MR biomarkers for assessing treatment 
follow-up, and the evaluation of adverse effects of treat-
ment on healthy brain tissue. Working Group ‘Multi-site 
data integration’ organised a workshop to develop a GDPR-
compliant template of an informed consent form, in col-
laboration with Open Brain Consent. This work resulted in 
the creation of a GDPR-compliant consent form and a data 
transfer agreement, which have been translated into twelve 
languages,3 with more translations planned to be released in 
the future [65–67] Working Group ‘Stakeholder relations’ 
has initiated relations with the EIBALL and GLASS, as well 
as the EORTC Imaging Group. Through its relationship with 
EIBALL and EORTC, GliMR supported a Horizon 2020 
grant application for setting up a European cancer imaging 
repository. Finally, the Working Group ‘Dissemination’ has 
set up several communication and dissemination channels, 
such as the official GliMR website (www.glimr .eu) [63], 
Twitter (@COST18206) and Instagram page (@glimr2.0), 
and a YouTube channel [68]. This Working Group is also 
in charge of creating and releasing a bi-monthly newsletter, 
issuing press releases and statements (such as the one for 
the ‘World Cancer Day 2020’), and summarizing the main 
outputs and news of GliMR.
5  Conclusion
Advancing MR imaging is crucial for the diagnosis, prog-
nosis, treatment planning and treatment follow-up of glioma 
patients and will allow a more personalized disease man-
agement approach. However, innovations are hampered by 
the scattered research landscape of advanced MRI for gli-
oma and the underrepresentation of specialists in this field 
within current European and international collaborations and 
organisations. Therefore, GliMR is building a pan-European 
and multidisciplinary network, to review and share current 
knowledge, draft and propose consensus guidelines, develop 
and share tools, and facilitate the execution of multi-centre 
advanced MRI studies for glioma. All researchers, health 
care professionals, public and private institutions, patient 
organisations and policy makers from countries already 
participating (as illustrated in Fig. 3), as well as from other 
COST, or even non-COST countries, are welcome to join 
our Action and Action activities, during the whole duration 
of the Action. More information on the procedure can be 
found on the official COST website [69], or by contacting 
the Action leadership through the website www.glimr .eu.
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